Italian Multicenter Study on Accuracy of 18F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma

DOI: 10.1016/j.clml.2018.04.002

Document Version
Accepted author manuscript

Link to publication record in Manchester Research Explorer

Citation for published version (APA):

Published in:
Clinical Lymphoma, Myeloma and Leukemia

Citing this paper
Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights
Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy
If you believe that this document breaches copyright please refer to the University of Manchester’s Takedown Procedures [http://man.ac.uk/04Y6Bo] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.
Accepted Manuscript

Italian multicenter study on accuracy of 18F-FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's Lymphoma


PII: S2152-2650(18)30011-9
DOI: 10.1016/j.clml.2018.04.002
Reference: CLML 1095

To appear in: Clinical Lymphoma, Myeloma and Leukemia

Received Date: 5 January 2018
Revised Date: 15 March 2018
Accepted Date: 11 April 2018


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Italian multicenter study on accuracy of 18F-FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's Lymphoma

A. Cistaro 1,2, L. Cassalia 1, C. Ferrara 3, N. Quartuccio 4, L. Evangelista 5, M. Bianchi 6, F. Fagioli 6,7, G. Bisi 8, S. Baldari 9, A. Zanella 10, M. Pillon 11, P. Zucchetta 10, M. Burrai 10, A. Sala 12, L. Guerra 13, P. Guglielmo 13, R. Burnelli 14, S. Panareo 15, F. Scalorbi 16, I. Rambaldi 15, A. Piccardo 17, A. Garaventa 18, D. Familiar 19, MC. Fornto 20, M. Mascarin 21, C. Altini 22, C. Ferrar 22, T. Perillo 23, N. Santoro 23, E. Borsatti 24, G. Rubini 22

Abbreviated title: Accuracy of 18F-FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin’s Lymphoma

1 Positron Emission Tomography Centre IRMET S.p.A., Affidea, Turin, Italy
2 Chief of PET Pediatric Study Group of Italian Association of Nuclear Medicine AIMN, Italy
3 Nuclear Medicine Unit, Umberto I Hospital, Siracusa, Italy
4 Wolfson Molecular Imaging Centre, The University of Manchester, Manchester
5 Nuclear Medicine and Molecular Imaging Unit, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
6 Pediatric Onco-Hematology and Stem Cell Transplant Division, City of Health and Science, Regina Margherita Children's Hospital, Turin, Italy
7 Chief of Italian Pediatric Oncology and Hematology Association AIEOP
8 Division of Nuclear Medicine, Azienda Ospedaliera Universitaria, Città della Scienza, Città della Scienza, Turin, Italy
9 Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphologic and Functional Images, University of Messina, Italy
10 Nuclear Medicine Service, Department of Medicine (DIMED), University Hospital, Padua, Italy
11 Department of Child and Woman Health, Oncology Hematology Division, University-Hospital of Padua, Padua, Italy
12 Maria Letizia Verga Center, MBBM Foundation – San Gerardo Hospital
13 Nuclear Medicine Unit, San Gerardo Hospital, Monza, Italy
14 Oncocematologia Pediatrica, Azienda Ospedaliera Universitaria, Ospedale Sant'Anna, Ferrara, Italy
15 Unit of Nuclear Medicine, Department of Diagnostic Imaging, S. Anna University Hospital, Ferrara, Italy
16 Nuclear Medicine Unit, University of Bologna, Italy
17 Nuclear Medicine Unit, Department of Diagnostic Imaging, E.O. Galliera Hospital, Genoa, Italy
18 Diapartamento di Emato-Oncologica Pediatrica Istituto G. Gaslini, Genova, Italy
19 Nuclear Medicine Department and PET/CT Center, ARNAS Garibaldi-Nesima, Catania, Italy
20 Department of Nuclear Medicine, Humanitas Research Hospital, Rozzano (Milano), Italy
21 S.S. Radioterapia Pediatrica e Area Giovani, IRCCS, Centro di Riferimento Oncologico Aviano, Pordenone, Italy
22 Nuclear Medicine Unit, University of Bari, Bari, Italy
23 Pediatric Hematology-Oncology Division, Department of Pediatrics, University of Bari, Bari, Italy
24 Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy

Corresponding Author:
Angelina Cistaro, MD, Ph. Positron Emission Tomography Centre IRMET, Affidea, V. O. Vigliani 89, Turin 10136, Italy.
Tel: +390113160158; Fax: +390113160828
E-mail: angelina.cistaro@affidea.it, angelicastaro@libero.it

Words of manuscript: 3021

The authors disclose of any personal or financial support or author involvement with organization(s) with financial interest in the subject matter – or any actual or potential conflict of interest.
This study investigated the utility of F-18-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared to bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin’s lymphoma (HL). 18F-FDG PET/CT shows high diagnostic performance in evaluating BMI in pediatric HL. BMB should be ideally reserved for patients with 18F-FDG PET/CT presenting doubtful bone marrow findings.

INTRODUCTION

Lymphoma is the third most common malignancy in the pediatric population (after leukemia and malignant brain tumors), comprising nearly 15% of childhood malignancies (53% Hodgkin Lymphoma [HL] and 47% non-Hodgkin Lymphoma [NHL]) (1). Classic HL accounts for more than 85% of cases, whereas nodular lymphocyte-predominant HL is a less common subtype of HL. The 5-year survival rate is 95% for HL (2,3). Once a lymphoma has been diagnosed, the extension of disease has to be assessed (4,5). HL is typically staged according to the Ann Arbor Staging Classification (6,7), which was updated by the Cotswolds report in 1989 (8). Therapeutic options, such as chemotherapy and/or radiotherapy, depend on the stage of disease at the time of diagnosis, being different in patients with localized stage from those with an advanced/disseminated disease (9-11).

Detection of lymphomatous bone marrow involvement (BMI), which accounts for 10% of pediatric HL cases, is clinically relevant because its presence can upstage the disease to stage IV and modify planning treatment (11-16).

In clinical/radiological stage IA or IIA disease the incidence of BMI has been reported to be even lower or close to 0% (17, 18). Due to the low incidence of BMI in early stages, the Cotswolds report recommends to restrict BMB to adult patients with computed tomography (CT) to stage III/IV disease or stage II disease with adverse unfavorable factors (8,19).

According to the latest guidelines issued by the Italian Association of Pediatric Onco-hematology (AIEOP), BMB should be preferentially done in symptomatic patients (class B) or those at stage ≥ III. However, in Italy, BMB is heterogeneously and commonly performed is paediatric patients with HL.
Nowadays, BMB remains the gold standard to determine bone marrow status but it has poor sensitivity (50%) for two main reasons: 1) the sample size may be small; 2) sometimes the BMI is focal (20,21). The main advantage of BMB is the acquisition of histological material. Moreover, a positive BMB is considered as a definitive proof of BMI. On the other hand, the major disadvantage of BMB is its invasiveness; it is a stressful and painful procedure, despite the use of local anesthesia.

18F-FDG-PET/CT has become an established method for lymphoma staging, and it may be potentially a non-invasive alternative or complementary method to BMB (22). A major advantage of 18F-FDG PET/CT is that it allows visualization of the entire marrow. However, the clinical value of PET/CT for the evaluation of the BMI in lymphoma is still under debate and investigation. Whilst there is a large body of evidence supporting the use of PET/CT for the evaluation of BMI in adults (23), few data are available about the diagnostic utility of PET/CT in relation to pediatric lymphoma for BM assessment (5).

The aim of the current multicentric Italian study is to define the utility of 18F-FDG PET/CT to identify BMI compared to BMB, in newly diagnosed HL pediatric patients.

MATERIALS AND METHODS

A total of 224 pediatric patients (mean age 14 years; range 4–18 years), with an initial diagnosis of HL, were retrospectively enrolled in this study across 10 Italian Nuclear Medicine departments: Padua (n=65; 2 centers), Turin (n=62; 2 centers), Monza (n=37), Bari (n=27), Genoa (n=21), Bologna (n=7); Ferrara (n=3) and Catania (n=2) (Table 1).

All patients underwent physical examination, routine blood parameters, contrast-enhanced CT scan of the neck/chest/abdomen, BMB and 18F-FDG PET/CT scan as part of the routine protocol for the initial staging. The Ann Arbor stage was determined without considering bone marrow uptake on the 18F-FDG PET/CT study.

The inclusion criteria were: 1) biopsy confirmation of HL; 2) availability of BMB and baseline 18F-FDG PET/CT results; 3) age<= 18 years; 4) availability of clinical and instrumental follow-up for at least 12 months.

Exclusion criteria were: 1) prior known and treated lymphoma; 2) presence of other concomitant malignancy; 3) previous chemo- or corticosteroid therapy; 4) interval between 18F-FDG PET/CT scan and BMB longer than 15 days.

The institutional review board granted a waiver for the patient informed consent due to the retrospective nature of this study.

18F-FDG PET/CT acquisition

All 18F-FDG PET/CT baseline scans were performed as whole-body scans (from the base of the skull to mid-thigh) after a 6-hr fasting period. Patients underwent blood glucose tests prior to administering 18F-FDG to ensure suitably low levels, received adequate pre-hydration, remained recumbent and silent in a warm room to ensure fewer artifacts and to minimize 18F-FDG uptake in muscles and brown fat activation.

PET/CT studies were obtained on the following PET/CT devices: Gemini TF64 (Philips), Gemini GXL (Philips), Gemini TF16 (Philips), Discovery LS (GE Healthcare), and Biograph TP16 (Siemens) according to the local
institutional scanning protocols. The emission data were acquired for 2–5 min per bed position (based on the available scan system) starting 60–90 min after intravenous injection of the body weight-adapted FDG dosage recommended according to the manufacturer guidelines for each scan model. Quality control procedures were carried out at regular intervals for all devices with strict adherence to local protocols, manufacturer guidelines, and EANM guidelines.

The low dose CT components of the PET/CT were used for both co-localization and attenuation correction of the PET emission data. Coronal, sagittal, and transversal PET/CT projections were reconstructed by iterative methods and analyzed using the manufacturers’ software.

18F-FDG PET/CT interpretation

At each institution, nuclear medicine physicians reviewed independently PET/CT images, blinded to the BMB results, with particular attention to the bone marrow.

18F-FDG PET/CT findings were considered positive for BMI in the presence of:

(-) isolated/multiple focal uptake in the bone marrow that could not be explained by benign findings on the underlying CT images or history (e.g. fractures);

(-) diffuse heterogeneous BMI with or without sites of intense focal uptake superior to liver or spleen background (in accordance with the Deauville Criteria (24)

In contrast 18F-FDG PET/CT was interpreted negative for BMI in the presence of:

(-) diffuse homogenous marrow involvement without sites of intense focal involvement [being reported that diffuse intense uptake is significantly related to anemia or inflammatory process (25-27)]

In doubtful cases images, a second opinion was requested to the leading centre of the multicenter study and the images were reviewed by an experienced nuclear medicine physician (13 years’ experience in pediatric PET/CT).

Bone marrow biopsy

Unilateral posterior iliac crest biopsy and marrow aspirate were pretherapeutically carried out according to AIEOP guidelines.

BMB were evaluated by experienced hematopathologists in each hospital; results were obtained from the individual reports and were not reviewed thereafter. BMB material was routinely formalin-fixed and paraffin embedded and subsequently evaluated morphologically on the basis of hematoxilin-eosin and Giemsa stains. As a rule, pan-T (at least CD3 and CD5), pan B (at least CD19 and CD20), CD30 and CD15 stains were performed in all cases.

In cases negative on BMB and positive on PET/CT imaging for BMI, the final diagnosis was established by follow-up imaging (up to 12 months): MRI with dedicated T1-weighted, T2-weighted and fat-suppressed T2-weighted sequences, bone scan and/or CT using bone window. In case of unavailability of imaging follow-up, clinical data were retrieved.
**Statistical Analysis**

Patients were categorized according to the absence or presence of BMI evaluated with BMB and 18F-FDG PET/CT results. For the whole patient cohort, positive and negative predictive values (PPV and NPV, respectively), sensitivity, specificity and accuracy were calculated separately for BMB and 18F-FDG PET/CT. Agreement between the 18F-FDG PET/CT and BMB was assessed using Cohen’s k computation.

**RESULTS**

**Patient characteristics**

Two hundred twenty-four patients were analyzed. 10 (4.4%) patients were at stage I, 99 (44.2%) at stage II, 65 (29%) at stage III and 50 (22.4%) at stage IV. Moreover, 155 (69%) patients had a nodular sclerosis, 24 (11%) a mixed cellularity, 4 (1.7%) a lymphocytic predominance, 19 (8.4%) a classical and 22 (9.9%) a non-classical lymphocytic predominance variant (Table 1).

**Diagnostic Performance of 18F-FDG PET/CT**

18F-FDG PET/CT was reported as negative for BMI in 193 cases. Sixteen out of 193 patients showed a diffuse FDG uptake in the bone marrow, and therefore originally reported as doubtful, later interpreted as negative for BMI, being negative at imaging follow-up and BMB; at BMB, 1/16 (6.25%) patients had a BMI. 192/193 (99.48%) patients had a negative BMB. Thus, 18F-FDG PET/CT was true negative in 192 patients and false negative in 1 patient for BMI.

18F-FDG PET/CT was reported as positive for BMI in 31 patients. BMB was positive in 9/31 patients and negative in 22/31. Subsequent CT and/or MR and/or bone scan confirmed PET/CT findings in 16 of these 22 patients.

The residual 6 patients were considered as false positive: 4 due to anaemia (Hb levels < 9 g/dl) and 2 for inflammation (ESR >20 mm/h and CPR > 200mg/L). The agreement between PET/CT and BMB was considered fair; the resulting Kohen for the two techniques was 0.4 (p<0.001; Table 2).

Sensitivity, specificity, NPV and PPV of 18F-FDG PET/CT for the evaluation of BMI were 96% (CI 95%: 89-100%), 97% (CI 95%: 95-99%), 99.5% (CI 95%: 98-100%) and 80.6% (CI 95%: 65.5-96%), respectively. On the contrary, the sensitivity, specificity, NPV and PPV of BMB were 38% (CI 95%: 20-57%), 100%, 92.5% (CI 95%: 89-96%) and 100%, respectively.

The distribution of stage disease and 18F-FDG PET/CT results are presented in Table 3. As illustrated, all 6 patients with false positive PET/CT results were at stage IIIA/B or IVA. Conversely, patients with true positive PET/CT results, had heterogeneously stage of disease (8 stage III-IV vs 8 stage II; 68% vs. 32%, respectively).

Out of 16 patients with a false positive BMB result, 8 subjects at stage II/A/IIB were truly positive at 18F-FDG PET/CT for BMI, thus changing the treatment management. In the remnant 8 patients at stage IIIA/B (n=5) and IVA/B (n=3), no change in management was reported. Conversely, 18F-FDG PET/CT was falsely positive in 6 patients at stage IIIB/IVA. All false positive PET cases (1: stage III and 5: stage IV) had negative imaging follow-up and negative BOM.

Only 1 falsely negative patient (stage IIIA), was reported on PET/CT, and did not lead to alteration of treatment planning. The false negative PET case resulted to be positive on both BOM and CT imaging.
One limitation of the study may be that image interpretation was not centralized, however the authors consistently used qualitative interpretation of imaging, evaluating the cases as positive or negative according to the Deauville Criteria; in doubtful cases, a second opinion was requested to the leading center of the multicenter study and the PET/CT images were reviewed by an experienced nuclear medicine physician (13 years’ experience in pediatric PET/CT).

**DISCUSSION**

The present manuscript reports data about the performance of BMB and 18F-FDG PET/CT for the identification of BMI in a series of 224 lymphoma pediatric patients.

The bone marrow is an important anatomical site where lymphomatous cells can reside. Detection of lymphomatous BMI may be clinically relevant from several perspectives. First, identifying lymphomatous cells in the bone marrow may aid in the diagnosis of lymphoma. Second, bone marrow assessment is a crucial part of the Ann Arbor system. Third, the presence of BMI may change the choice of therapy. Fourth, knowing all sites of lymphomatous involvement, including bone marrow sites, allows monitoring the effects of therapy.

BMB is an invasive procedure that provides histologic examination of just a small bone marrow sample, whereas 18F-FDG PET/CT is a non-invasive method that lacks histologic material but allows visualization of the entire marrow (28).

The distribution of 18F-FDG throughout the skeleton follows that of the red marrow (29, 30), which changes during normal aging (31). Under normal conditions the bone marrow shows homogeneously low uptake of 18F-FDG, with the bone marrow appearing less intense than the liver. However, as para-physiological variants, increased 18F-FDG activity in the bone marrow can be observed in patients undergoing, or soon after the end, chemotherapy (usually within one month), patients with hyperplasia and hematopoietic stimulation from anemia and patients who received granulocyte colony-stimulating factor (CSF), hematopoietic growth factor, or erythropoietin (32).

In our pediatric patient population, we found that 18F-FDG PET/CT was negative for BMI in 86% of patients. Based on the gold standard, 18F-FDG PET/CT resulted TN in 192 patients, FN in 1 patient, TP in 25 and FP in 6 subjects. However, this latter finding was more frequent in patients at advanced stages (IIIA/B and IVA). On the other hand, we found that BMB showed a high number of FN findings, thus reporting a lower sensitivity than 18F-FDG PET/CT imaging (38% vs 96%, respectively). Nevertheless, BMB did not show any FP results.

To date in literature, there are a lot of data about the role of 18F-FDG PET/CT in the evaluation of BMI in adult patients with HL, while data relative to pediatric lymphoma remain limited.

In adults, 18F-FDG PET/CT can be proposed as a very sensitive method for the detection of BMI that may overcome the diagnostic yield of BMB (33-35). Furthermore, Adams et al reported that, in a series of 235 adult patients, about 70% of them experienced procedure-related pain, reporting severe pain in one-third of these patients (36). Nevertheless, at least until recently, there was still a lot of variability in the use or the omission of BMB in Hodgkin lymphoma patients in routine clinical practice (37).

In pediatric population, some retrospective studies have demonstrated that 18F-FDG PET/CT is superior
than conventional imaging modalities (i.e. CT, ultrasound, magnetic resonance imaging (MRI) or bone scintigraphy) in the primary staging of lesions, both in Hodgkin's and non-Hodgkin's disease (38-41; Table 4). In the initial staging of pediatric lymphoma, 18F-FDG PET/CT findings are usually consistent with CT scan findings. Although its specificity is decreased when the disease is located in anatomical sites where physiologic 18F-DG uptake takes place (42-44); in 9.4–22.6 % of the cases, 18F-FDG PET/CT may show abnormalities that are not displayed by other imaging methods and is useful during disease staging and treatment planning (45,46). Overall, all studies were performed by considering all site of lesions (nodal and extra-nodal) without a specific information of BMI. Additionally, our study showed that 18F-FDG PET/CT was more accurate also in the detection of BMI than BMB (sensitivity: 96% vs 38%, respectively).

Similar results were reported by Purz et al. (47) who compared the results from BMB and 18F-FDG PET/CT for the diagnosis of BMI in 175 pediatrics patients with HL stage greater than IIA. The authors concluded that 18F-FDG PET may safely replace BMB in routine staging procedure in pediatric HL, particularly in patients with a focal BMI. Salaun et al. (27) retrospectively analyzed 106 pediatric and adult patients who underwent 18F-FDG PET/CT for initial staging of HL and concluded that an increased bone marrow uptake could more likely be due to inflammation than BMI and only the presence of bone foci should be interpreted as bone involvement on visual 18F-FDG PET/CT evaluation. In the present study, we considered a diffuse bone marrow involvement with or without the presence of the focal foci. The interpretation of PET/CT was made by using the Deauville Criteria. These criteria are mainly employed for the evaluation of the interim response to therapy (24), however they can be applied also in the initial staging of disease.

In a recent study presented at the Annual Congress of the Society of Nuclear Medicine, Chen et al. (48) reported that in 75 pediatric patients with diagnosed NHL, 18F-FDG PET/CT demonstrated a higher sensitivity and specificity than BMB (94% and 98% vs. 55% and 100%, respectively for 18F-FDG PET/CT and BMB).

In our analysis, we found that 6 patients at stage II, falsely assessed by BMB, were reclassified as stage IV after the inclusion of 18F-FDG PET/CT in the diagnostic algorithm, changing both clinical stage and therapeutic management. Differently, false positive findings at 18F-FDG PET/CT did not change neither stage of disease nor therapeutic management. Furthermore, on the basis of these results, all 31 patients in our series with BMI would be classified as having advanced stage disease. Thus, the identification of BMI by BMB would not have altered treatment recommendations for any of these patients. Of interest, BMB-based lymphomatous bone marrow involvement has not been proven to be a major adverse predictor of outcome in Hodgkin lymphoma. In the cohort on the development of the International Prognostic Score (IPS) in advanced stage Hodgkin lymphoma, progression-free survival (PFS) and overall survival (OS) in 614 patients with BMB-proven BMI (60% and 70% respectively) were not significantly different from those in 1351 patients without BMI according to BMB (61% and 74% respectively) (4). This findings indicate that omission of BMB would not result in a major decline in prognostic power of the IPS in patients with advanced stage disease (49). In early stage disease, the incidence of BMI is extremely low, and the prognostic value of BMB in this subpopulation has therefore not been well documented. However our study shows that 18F-FDG PET/CT is superior to BMB in the identification of this subgroup of patients, changing the stage and patient management. An interest finding of our study is the modest specificity of +BM PET compared to bone marrow biopsy; this fact could reflect an highly heterogenous environment in the BM indicating that a single site biopsy is not perfectly adequate in depicting the heterogeneous characteristics of the bone marrow in pediatric HL.

However, the present study has some limitations. Firstly, the retrospective collection of data can represent a
limit. Secondly, all collected cases were considered by a multicenter analysis; however the interpretation of 18F-FDG PET/CT scans was made by a visual analysis rather than semiquantitative one. Lastly, since image-based follow-up was carried out separately in each centre rather than in a single centre, variable experience of examining physicians and different imaging protocols and facilities may have lead to different grades of reliability and accuracy of the reference standard.

CONCLUSIONS

We reported data on 18F-FDG PET/CT and BMB performance in the diagnosis of BMI in a series of 224 pediatric patients with HL. Our results show that 18F-FDG PET/CT has a high diagnostic power for the evaluation of BMI involvement in HL supporting the concept that BMB should not be systematically performed in all the patients, but may be reserved exclusively for patients with doubtful 18-FDG bone marrow findings.

REFERENCES


Legend:

Figure 1

A-C: diffuse FDG bone marrow uptake pattern in the skeleton reported as doubtful bone marrow finding. The BMB resulted to be negative.

D-F: focal FDG uptake interpreted as a FDG-avid bone marrow lesion. The BMB resulted concordant with the FDG finding.
<table>
<thead>
<tr>
<th>Patient number</th>
<th>224</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Age</td>
<td>14 years (4-18)</td>
</tr>
<tr>
<td>Histotype</td>
<td>155 nodular sclerosis</td>
</tr>
<tr>
<td></td>
<td>24 mixed cellularity</td>
</tr>
<tr>
<td></td>
<td>22 non-classical lymphocytic predominance variant</td>
</tr>
<tr>
<td></td>
<td>19 classical variant</td>
</tr>
<tr>
<td></td>
<td>4 lymphocytic variant</td>
</tr>
<tr>
<td>Stage</td>
<td>I: 10</td>
</tr>
<tr>
<td></td>
<td>II: 99</td>
</tr>
<tr>
<td></td>
<td>III: 65</td>
</tr>
<tr>
<td></td>
<td>IV: 50</td>
</tr>
</tbody>
</table>

Table 1: patient demographics
Table 2. Agreement between 18F-FDG PET/CT and bone marrow biopsy

<table>
<thead>
<tr>
<th></th>
<th>Negative BMB</th>
<th>Positive BMB</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative PET/CT</td>
<td>192</td>
<td>1</td>
<td>193</td>
</tr>
<tr>
<td>Positive PET/CT</td>
<td>22</td>
<td>9</td>
<td>31</td>
</tr>
<tr>
<td>Total</td>
<td>214</td>
<td>10</td>
<td>224</td>
</tr>
</tbody>
</table>

K agreement: 0.398 (p<0.001)
Table 3. Distribution of PET/CT results in accordance with clinical staging

<table>
<thead>
<tr>
<th>PET/CT</th>
<th>N pts</th>
<th>Stage I</th>
<th>Stage II</th>
<th>Stage III</th>
<th>Stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Stage IA</td>
<td>Stage IB</td>
<td>Stage IIA</td>
<td>Stage IIB</td>
</tr>
<tr>
<td>TP</td>
<td>25</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>TN</td>
<td>192</td>
<td>9</td>
<td>1</td>
<td>58</td>
<td>33</td>
</tr>
<tr>
<td>FP</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FN</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>224</td>
<td>10</td>
<td>99</td>
<td>65</td>
<td>50</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PET/CT</th>
<th>N pts</th>
<th>Stage I</th>
<th>Stage II</th>
<th>Stage III</th>
<th>Stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Stage IA</td>
<td>Stage IB</td>
<td>Stage IIA</td>
<td>Stage IIB</td>
</tr>
<tr>
<td>TP</td>
<td>25</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>TN</td>
<td>192</td>
<td>9</td>
<td>1</td>
<td>58</td>
<td>33</td>
</tr>
<tr>
<td>FP</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FN</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>224</td>
<td>10</td>
<td>99</td>
<td>65</td>
<td>50</td>
</tr>
</tbody>
</table>
Table 4. Collection of published data about 18F-FDG PET/CT and CI in initial staging of disease.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year of pub</th>
<th>Number of patients</th>
<th>FDG PET or PET/CT</th>
<th>Conventional imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sensitivity</td>
<td>Specificity</td>
</tr>
<tr>
<td>Kabickova et al (37)</td>
<td>2006</td>
<td>55 children and adolescent</td>
<td>96.5%</td>
<td>100%</td>
</tr>
<tr>
<td>Furth C, et al (38)</td>
<td>2006</td>
<td>33 pediatrics</td>
<td>84%</td>
<td>95%</td>
</tr>
<tr>
<td>Cheng et al (39)</td>
<td>2013</td>
<td>51 pediatrics</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>(30 HL and 21 NHL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>London K et al (40)</td>
<td>2011</td>
<td>71 pediatrics</td>
<td>95.9%</td>
<td>99.7%</td>
</tr>
</tbody>
</table>

HL: Hodgkin lymphoma; NHL: non-Hodgkin lymphoma; NA: not available; NPV: negative predictive value; PPV: positive predictive value